IDEAYA Biosciences Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update
2
Safe Harbor Statement
Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events
or the future financial performance of IDEAYA Biosciences, Inc. (the "Company") and involve known and unknown risks, uncertainties and other factors
that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those
expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will,"
"could," "would," "should," "expect," "plan," "anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential" or other comparable terminology. All
statements other than statements of historical fact could be deemed forward-looking, including any expectations regarding the Company's target discovery
platform or new target validation efforts as creating opportunities for research and development initiatives; any projections of financial information,
market opportunities, cash runway or profitability; any statements about historical results that may suggest trends for the Company's business; any
statements of the plans, strategies, and objectives of management for development programs or future operations; any statements about the timing of
preclinical research, clinical development, regulatory filings, manufacturing or release of data; any statements of expectation or belief regarding future
events, potential markets or market size, technology developments, or receipt of cash milestones, option exercise fees or royalties; and any statements of
assumptions underlying any of the items mentioned. The Company has based these forward-looking statements on its current expectations, assumptions,
estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking
statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and
other important factors may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-
looking statements. The forward-looking statements in this presentation are made only as of the date hereof. For a further description of the risks and
uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of
the Company in general, see the Company's periodic filings with the Securities and Exchange Commission (the "SEC"), including its Annual Report on Form
10Q for the quarter ended September 30, 2021, and any current and periodic reports filed thereafter. Except as required by law, the Company assumes no
obligation and does not intend to update these forward-looking statements or to conform these statements to actual results or to changes in the
Company's expectations.
This presentation concerns anticipated products that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food
and Drug Administration (FDA). It is currently limited by Federal law to investigational use, and no representation is made as to its safety or effectiveness
for the purposes for which it is being investigated.
BIOSCIENCES
IDEAVAView entire presentation